Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.
Williams EA, Ravindranathan A, Gupta R, Stevers NO, Suwala AK, Hong C, Kim S, Yuan JB, Wu J, Barreto J, Lucas CG, Chan E, Pekmezci M, LeBoit PE, Mully T, Perry A, Bollen A, Van Ziffle J, Devine WP, Reddy AT, Gupta N, Basnet KM, Macaulay RJB, Malafronte P, Lee H, Yong WH, Williams KJ, Juratli TA, Mata DA, Huang RSP, Hiemenz MC, Pavlick DC, Frampton GM, Janovitz T, Ross JS, Chang SM, Berger MS, Jacques L, Song JS, Costello JF, Solomon DA.
Williams EA, et al.
Neuro Oncol. 2023 Dec 8;25(12):2221-2236. doi: 10.1093/neuonc/noad121.
Neuro Oncol. 2023.
PMID: 37436963
Free PMC article.
Functional studies revealed these SOX10 indel mutations have retained DNA binding capacity but impaired transactivation of glial differentiation and myelination gene programs. CONCLUSIONS: We thus speculate that SOX10 indel mutations drive a unique subtype of schwan …
Functional studies revealed these SOX10 indel mutations have retained DNA binding capacity but impaired transactivation of glial diff …